Αποτελέσματα Αναζήτησης
1 Μαρ 2022 · This systematic review summarizes the literature examining the possible clinical benefits of EDTA chelation therapy in patients with preexistent cardiovascular disease. This is the largest review to date, including 4 clinical trials, 15 prospective before/after studies, and 5 retrospective case series assessing mortality, disease severity ...
- View Epub
View Epub - Chelation Therapy in Patients With...
- View Epub
13 Ιουν 2023 · Some researchers say chelation therapy can treat heart disease because the medicine may stick to — and remove — calcium found in deposits that clog arteries. However, chelation therapy for heart disease remains controversial.
Chelation therapy is a process in which a substance is delivered intravenously (through the veins) to bind metals or minerals so they can be removed from the body via urination. When it’s used as a complementary treatment for heart disease, a course of treatment can require 20 to 40 weekly infusions lasting several hours each.
Chelation therapy is promoted as a form of alternative medicine to treat atherosclerosis and relieve symptoms of cardiovascular disease . It has been suggested to be a safe, relatively inexpensive, non‐surgical method of restoring blood flow in atherosclerotic vessels, thus preventing chronic symptoms such as angina pectoris and claudication ...
To summarise all the clinical evidence, from controlled and uncontrolled studies, for or against the effectiveness and efficacy of chelation therapy for coronary heart disease (CHD).
1 Μαρ 2022 · Background. EDTA is an intravenous chelating agent with high affinity to divalent cations (lead, cadmium, and calcium) that may be beneficial in the treatment of cardiovascular disease (CVD). Although a large randomized clinical trial showed benefit, smaller studies were inconsistent.
Key findings. Twenty-four studies (15 prospective studies, 5 retrospective case series, 4 randomized clinical trials) assessed repeated ethylenediaminetetra-acetic acid (EDTA) chelation treatment in patients with preexistent cardiovascular disease.
